PTCT
$65.30-1.77 (-2.65%)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna a...
Recent News
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations
What recent performance data suggests about PTC Therapeutics PTC Therapeutics (PTCT) has been moving in different directions across time frames, with a 0.1% return over the past day and 5.9% over the past week, compared with a 3% decline over the past month. Over the past 3 months, the stock shows a 14.6% decline, while the 1 year total return stands at 18.4%. Looking further back, total returns over 3 and 5 years are 43.7% and 33.9% respectively. At the last close of US$67.08, PTC...
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
KROS Stock: What to Know About Rinvatercept in DMD
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.